Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):415-21.

PMID:
10772527
2.

Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.

Mueller BU, Pizzo PA, Farley M, Husson RN, Goldsmith J, Kovacs A, Woods L, Ono J, Church JA, Brouwers P, et al.

J Pediatr. 1994 Jul;125(1):142-6.

PMID:
8021765
3.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
4.
5.

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

Hughes W, McDowell JA, Shenep J, Flynn P, Kline MW, Yogev R, Symonds W, Lou Y, Hetherington S.

Antimicrob Agents Chemother. 1999 Mar;43(3):609-15.

6.

Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.

Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Urien S, Foulongne V, Van De Perre P, Tréluyer JM, Msellati P.

Antimicrob Agents Chemother. 2009 Oct;53(10):4399-406. doi: 10.1128/AAC.01187-08. Epub 2009 Jul 6.

7.

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A.

Antimicrob Agents Chemother. 2016 May 23;60(6):3676-86. doi: 10.1128/AAC.02678-15. Print 2016 Jun.

8.

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P, et al.

J Infect Dis. 1992 Jan;165(1):99-104.

PMID:
1727902
9.

Food-induced reduction in bioavailability of didanosine.

Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH.

Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):503-7.

PMID:
1934863
10.

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW.

Antimicrob Agents Chemother. 2000 Apr;44(4):1029-34.

11.

Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

Mueller BU, Butler KM, Stocker VL, Balis FM, Brouwers P, Jarosinski P, Husson RN, Lewis LL, Venzon D, Pizzo PA.

Pediatrics. 1994 Nov;94(5):724-31.

PMID:
7936903
12.
13.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
14.

Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.

Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez AD, Gandia J, O'Sullivan MJ, Clax P, Huang S, Unadkat JD.

J Infect Dis. 1999 Nov;180(5):1536-41.

PMID:
10515813
15.

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.

Knupp CA, Milbrath R, Barbhaiya RH.

J Clin Pharmacol. 1993 Jun;33(6):568-73.

PMID:
8366182
16.

Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?

Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S.

Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1.

17.

Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.

Chen C, Bujanover S, Kareht S, Rapoport AM.

Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.

PMID:
25546369
18.

Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.

Wintergerst U, Rolinski B, Sölder B, Bogner JR, Wolf E, Jäger H, Roscher AA, Belohradsky BH.

Antimicrob Agents Chemother. 1999 Mar;43(3):699-701.

19.

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.

Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S.

Antimicrob Agents Chemother. 1999 Mar;43(3):603-8.

20.

Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.

Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M, Lee K, Wajszczuk CP.

Antimicrob Agents Chemother. 1996 Mar;40(3):767-71.

Supplemental Content

Support Center